Report Overview

The Australian Wilson Disease Therapeutics Market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The Wilson disease (WD), also known as hepatolenticular degeneration, and progressive lenticular degeneration, is a rare genetic disorder of copper metabolism characterized by excess copper stored in various body tissues, particularly the liver, brain, and corneas of the eyes. The disease is progressive and if left untreated, may cause liver (hepatic) failure, haemolytic crisis, central nervous system dysfunction, and death. It is caused by a mutation of the ATP7B gene and is inherited in an autosomal recessive manner. Early diagnosis and treatment may prevent serious long-term disability and life-threatening complications. Treatment is aimed at reducing the amount of copper accumulated in the body by chelation therapy and maintaining normal copper levels thereafter.

Wilson disease typically appears in people under 40 years old. Without treatment, life expectancy is estimated to be 40 years, but with prompt and efficient treatment, patients may have a normal lifespan. Wilson disease is a rare disorder that affects males and females in equal numbers. The disease is found in all races and ethnic groups.



Market Growth Drivers

The Wilsons disease Therapeutics market is primarily driven by the financial incentives and overall rewards for the successful development of drugs for the treatment and diagnosis of rare diseases and conditions. Moreover, the increasing awareness regarding Wilsons disease by various organization and association and its symptoms along with the growing population all over the world is expected to fuel the treatment market.

However, technological advancement in treatment and diagnosis and rising genetic inherited disorders also boost up the market growth. Moreover, increasing demand for treatment and rising patient awareness about different treatment options, increasing medical tourism and rising investment by market players also generate market opportunities.

However, the high initial investments resulting in higher per patient treatment cost, adverse effects related to the treatment and lower treatment rates may hampers the market over the forecast period.